A Pilot Phase II Study of a Nucleoside Sparing Regimen of Dolutegravir + Atazanavir/r in HIV-1 Infected Patients With Detectable Viremia (DOLATAV Study)
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Atazanavir (Primary) ; Dolutegravir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms Dolatav
- 10 Jun 2017 Biomarkers information updated
- 24 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 08 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.